Cantor Fitzgerald Reiterates a Buy Rating for BioMarin Pharmaceutical (BMRN)

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best healthcare stocks with the highest upside. In a report released on October 14, Cantor Fitzgerald analyst Olivia Brayer reiterated a Buy rating for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). However, the analyst slashed the firm’s price target on the stock from $90 to $80.

J.P. Morgan analyst Jessica Fye also maintained a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on October 9, setting a price target of $119.

In other developments, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced new data from 14 studies on September 8, presenting it at the American Society for Bone and Mineral Research 2025 (ASBMR) Annual Meeting in Seattle.

The presentation included results showing that treatment with VOXZOGO® (vosoritide) resulted in “anatomical improvements in spinal morphology in young children”, along with “continued efficacy in children who received the medicine after the onset of puberty”.

Following this update, BMO Capital analyst Kostas Biliouris maintained a Buy rating on the stock, keeping the price target at $115 and supporting the optimistic outlook with BioMarin Pharmaceutical Inc.’s (NASDAQ:BMRN) promising growth prospects.

The analyst cited the potential expansion of Palynziq into the adolescent market as a key driver for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), potentially increasing its market share.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) develops and commercializes therapies for serious and life-threatening medical conditions and rare diseases. The company’s product pipeline includes Valoctocogene roxaparvovec, Vosoritide, and BMN 307.

While we acknowledge the potential of BMRN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.